FDA approves Sunharbo, the first factor XIa inhibitor, for repeat-stroke risk

The Food and Drug Administration approved Sunharbo (asundexian) on 9 November, the first drug in a new class called factor XIa inhibitors [s1]. It is cleared for use alongside antiplatelet therapy to reduce the risk of stroke in adults who have recently had a mild-to-moderate non-cardioembolic ischaemic stroke — a stroke caused by a clot that did not originate in the heart — or a high-risk transient ischaemic attack (TIA), the warning event often called a "mini-stroke" [s1].

The indication is narrow and worth reading closely. This is secondary prevention: it is for people who have already had one of these events and are at risk of another, not a treatment given during a stroke, and not a general blood thinner for anyone with a clotting risk. The agency is also explicit about one group the drug is not for — Sunharbo is not approved for stroke prevention in patients with atrial fibrillation, the irregular-heartbeat condition where anticoagulants are a mainstay [s1].

What a factor XIa inhibitor is

Blood clotting runs through a cascade of proteins, each activating the next. Factor XIa sits in that cascade, and the hope behind targeting it is a long-standing one in cardiology: that blocking this particular step might prevent harmful clots while causing less bleeding than older anticoagulants, which act on steps more central to normal clot formation. Asundexian is the first drug of this kind the FDA has cleared, so the approval is a test of that premise in practice, not just in theory [s1].

The evidence

Approval rests on OCEANIC-STROKE, a multicentre, randomised, double-blind, placebo-controlled phase 3 study that enrolled 12,327 adults [s1]. Participants had recently had a non-cardioembolic ischaemic stroke, with a score of 15 or below on the NIH Stroke Scale (a measure where lower numbers mean a less severe stroke), or a high-risk TIA, and were randomly assigned to Sunharbo or placebo within 72 hours of symptom onset [s1]. Both groups also received antiplatelet therapy, so the trial tested the drug as an addition to standard care, not against nothing [s1].

Over a median of 14.2 months of treatment, Sunharbo 50 mg once daily significantly reduced the risk of ischaemic stroke by 26% compared with placebo [s1].

That is a genuine reduction in the event the drug is meant to prevent, measured in a large, blinded, placebo-controlled trial — a far stronger design than the single-arm studies behind many recent approvals. The figure to keep in proportion is that 26% is a relative reduction: it describes how much the stroke rate fell in proportion to the placebo group's rate, not the absolute number of strokes avoided, which depends on how high that underlying risk was.

The bleeding question

Every anticoagulant trades clot prevention against bleeding risk, and the factor XIa class was built on the bet that this trade-off might be gentler. The trial's result is mixed rather than a clean win. The overall rate of major bleeding was similar between the Sunharbo and placebo groups — but it was increased with Sunharbo in patients older than 75 and during the first 90 days of treatment, and gastrointestinal bleeding occurred more commonly with the drug than with placebo [s1]. So the reassuring headline on overall major bleeding conceals two groups — the elderly and the newly treated — in whom the risk is higher, which is exactly where prescribing caution will matter most.

The most frequently reported adverse reaction, in 3% or more of treated patients, was diarrhoea [s1].

How it is used, and its limits

Sunharbo is a 50 mg tablet taken once daily [s1]. The label sets out several practical boundaries. It should not be combined with medicines that are both P-glycoprotein and strong CYP3A4 inducers — carbamazepine is the example given — because those can lower the drug's effectiveness [s1]. It is not recommended in patients with moderate or severe liver impairment [s1]. And because it thins the blood, it should be withheld for at least 24 hours before elective surgery or invasive procedures, and for at least 24 hours after clot-dissolving thrombolysis given for an acute stroke [s1].

The FDA granted the drug Fast Track and Priority Review designations, pathways meant to speed the review of treatments for serious conditions; the approval was granted to Bayer HealthCare Pharmaceuticals [s1]. Unlike an accelerated approval, this is a standard approval resting on a completed outcomes trial, so the evidence base is more settled than for a drug cleared on a surrogate marker.

What to watch

The open questions are the ones the trial result raises rather than closes. How the bleeding signal in people over 75 and in the first three months plays out in routine use will shape who is offered the drug. And because it is not approved for atrial-fibrillation patients, prescribers will have to keep the narrow secondary-prevention indication firmly in view. For now, a class long promised as a safer anticoagulant has its first real-world approval, on evidence strong enough to take seriously and specific enough to read carefully [s1].

Red flags: unusual or heavy bleeding, black or bloody stools, or signs of a new stroke — sudden face drooping, arm weakness or speech difficulty — warrant urgent medical attention. This article describes regulatory news and is not medical advice. Decisions about stroke prevention are for patients and their treating clinicians.